Developed in Japan, argatroban was the first licensed synthetic direct thrombin inhibitor. Recently approved in some European countries, argatroban is marketed for anticoagulation in adult patients with heparin-induced thrombocytopenia type II (HIT type II) who require parenteral antithrombotic therapy.

Certain pages are intended for healthcare professionals only.